Picture of Mauna Kea Technologies SA logo

ALMKT — Mauna Kea Technologies SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Brief: Mauna Kea Announces FDA Clearance For The Use Of Cellvizio

April 12 (Reuters) - Mauna Kea Technologies SAS  MKEA.PA :
    * ANNOUNCES THE FIRST FDA 510(K) CLEARANCE FROM THE FDA FOR
THE
USE OF CELLVIZIO IN A NEW CLASS OF ENDOSCOPIC, LAPAROSCOPIC AND
NEEDLE-BASED PROCEDURES GUIDED BY MOLECULAR IMAGING
    * THIS U.S. FDA CLEARANCE IS FOR A NEW CLINICAL INDICATION
FOR THE
USE OF CELLVIZIO IN FLUORESCENCE IMAGING OF TISSUES TARGETED BY
A MOLECULAR MARKER, PAFOLACIANIN, MARKETED AS CYTALUX™ AND
MANUFACTURED BY ON TARGET LABORATORIES

Source text: [https://bit.ly/37Jw9IQ]
Further company coverage:  MKEA.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Mauna Kea Technologies SA

See all news